Lupin unveils bipolar disorder drug Divalproex Sodium ER Tablets in US
Mumbai, Baltimore: Pharma major Lupin Limited has recently announced the launch of Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
The product will be manufactured at Lupin's Nagpur facility in India.
Divalproex Sodium ER Tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote ExtendedRelease (ER) Tablets, 250 mg and 500 mg, of AbbVie Inc., indicated for:
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.